CALOR试验最终分析:化疗对ER阴性及ER阳性乳腺癌孤立局部区域复发的疗效
CALOR是一项开放标签随机试验,纳入162例完全切除的乳腺癌孤立局部区域复发(ILRR)患者,随机接受化疗或不化疗。
要点
- ER阴性ILRR患者化疗显著改善DFS,10年DFS 70% vs 34%。
- ER阳性ILRR患者化疗无DFS获益,10年DFS 50% vs 59%。
- ER阴性ILRR的乳腺癌无复发生存亦显著改善(HR 0.29)。
核心结论
- 最终分析证实化疗对已切除的ER阴性ILRR患者有益,不支持ER阳性ILRR患者使用化疗。
研究设计与样本
- CALOR为开放标签随机试验,2003年8月至2010年1月入组162例完全切除的单侧乳腺癌ILRR患者,58例ER阴性、104例ER阳性。
- 患者随机接受化疗或不化疗,按既往化疗、激素受体状态和ILRR部位分层;激素受体阳性者接受辅助内分泌治疗。
主要发现
- 中位随访9年,ER阴性组27例DFS事件,ER阳性组40例DFS事件。
- ER阴性ILRR患者化疗对比不化疗的DFS HR为0.29(95%CI 0.13-0.67),10年DFS分别为70%和34%。
- ER阳性ILRR患者化疗对比不化疗的DFS HR为1.07(95%CI 0.57-2.00),10年DFS分别为50%和59%。
关键数值与推荐
- ER阳性ILRR患者10年DFS差异为-9%(50% vs 59%)。
临床怎么用
- 对于完全切除的ER阴性ILRR乳腺癌患者,应考虑辅助化疗以改善无病生存。
- 对于ER阳性ILRR患者,化疗未显示获益,不应常规推荐化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Isolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)-negative ILRR, but additional follow-up was required in ER-positive ILRR. Patients and Methods CALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral breast cancer. Eligible patients were randomly assigned to receive CT or no CT and stratified by prior CT, hormone receptor status, and location of ILRR. Patients with hormone receptor-positive ILRR received adjuvant endocrine therapy. Radiation therapy was mandated for patients with microscopically involved margins, and anti-human epidermal growth factor receptor 2 therapy was optional. End points were disease-free survival (DFS), overall survival, and breast cancer-free interval. Results From August 2003 to January 2010, 162 patients were enrolled: 58 with ER-negative and 104 with ER-positive ILRR. At 9 years of median follow-up, 27 DFS events were observed in the ER-negative group and 40 in the ER-positive group. The hazard ratios (HR) of a DFS event were 0.29 (95% CI, 0.13 to 0.67; 10-year DFS, 70% v 34%, CT v no CT, respectively) in patients with ER-negative ILRR and 1.07 (95% CI, 0.57 to 2.00; 10-year DFS, 50% v 59%, respectively) in patients with ER-positive ILRR ( Pinteraction = .013). HRs were 0.29 (95% CI, 0.13 to 0.67) and 0.94 (95% CI, 0.47 to 1.85), respectively, for breast cancer-free interval ( Pinteraction = .034) and 0.48 (95% CI, 0.19 to 1.20) and 0.70 (95% CI, 0.32 to 1.55), respectively, for overall survival ( Pinteraction = .53). Results for the three end points were consistent in multivariable analyses adjusting for location of ILRR, prior CT, and interval from primary surgery. Conclusion The final analysis of CALOR confirms that CT benefits patients with resected ER-negative ILRR and does not support the use of CT for ER-positive ILRR.
引用
- Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018. PMID: 29443653. doi:10.1200/JCO.2017.76.5719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。